stockrow
Friday 6 November 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
- EPS
- +57.5%
- Free cash flow
- −60.5%
Quarter to June 2026, against a year earlier
0.55
0.01
−1.79%
Follow CTXR
Alert me
Citius Pharmaceuticals, Inc. (CTXR) P/E ratio
Citius Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)